Valentino Conter
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
PURPOSE Modern ALL therapy aims to reduce toxicity, while maintaining and improving the current high cure rates. Acute and late sequelae of anthracyclines are of major concern. The AIEOP-BFM ALL 2009 trial aimed to clarify the need for anthracyclines in low-risk patients. PATIENTS AND METHODS After 2 weeks of induction therapy, which included two daunorubicin (DNR) doses once weekly (30 mg/m 2 each) as part of a 4-drug therapy, patients age 1-17 years with newly diagnosed non–high-risk B-ALL either positive for ETV6::RUNX1 or with rapid treatment response, as assessed by induction day-15 evaluation, were randomly assigned to receive either two additional doses of DNR (control arm [CA]) or no further DNR during induction (experimental arm [EA]). Patients treated as randomly assigned were included in the primary analysis on noninferiority in event-free survival (EFS). Adverse reactions of special interest (ARSI) were analyzed in the as-treated population. RESULTS Of 6,136 patients enrolled in AIEOP-BFM ALL 2009, 2,514 patients (41.0%) were eligible for this random assignment, with 82.7% actually randomly assigned (EA: n = 1,040 and CA: n = 1,039). The 5-year EFS was 92.5% (SE 0.8%) in CA and 92.2% (SE 0.9%) in EA. Accordingly, cumulative incidence of relapse was 5.8% (SE 0.7%) and 5.7% (SE 0.7%), and overall survival was 97.6% (SE 0.5%) and 97.4% (SE 0.5%) in CA and EA, respectively. Life-threatening and fatal ARSI were similar in the two arms, but there was a three times lower incidence of invasive fungal infections in the EA (0.5% v 1.5%, P = .02). CONCLUSION A reduced DNR dose during induction did not compromise the outcome of patients with favorable prognostic factors but did diminish infectious toxicity indicated by the lower rate of invasive fungal infections.
Year:
2025
Over the past decade, the management of childhood acute lymphoblastic leukemia (ALL) has undergone remarkable advancements. This review explores the transition from conventional chemotherapy protocols to precision medicine approaches, highlighting improvements in diagnostic techniques, therapeutic strategies, and personalized treatments within front-line protocols. Key developments include enhanced minimal residual disease detection, the advent of immunotherapies, targeted therapies, and the integration of artificial intelligence. Despite these advancements, challenges remain in ensuring global access and equity. This article discusses the current state of ALL treatment and anticipates future directions in the field.
Year:
2025
To improve the outcome of pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) patients, the AIEOP‐BFM ALL 2009 trial modified T‐ALL stratification and treatment based on AIEOP‐BFM ALL 2000 and other pediatric ALL groups' results. This report aims to describe the outcome of T‐ALL patients in trial AIEOP‐BFM ALL 2009 and evaluate prognostic features defined within the end of induction (EOI) therapy, for future protocols stratification and interventions. From 06/2010 to 02/2017, 872 T‐ALL patients, aged 1–17, were enrolled. High risk (HR) criteria were prednisone poor response (PPR), Day 15 flow cytometry minimal residual disease (MRD) ≥ 10%, no complete remission at EOI, or polymerase chain reaction (PCR)‐MRD ≥ 5 × 10 −4 at end of consolidation (EOC). Three Cox regression models on event‐free survival (EFS) evaluated prognostic factors. Overall, 5‐year EFS and survival were 79.9% ± 1.4% and 84.9% ± 1.2% with cumulative incidence of relapse (CIR) and death of 13.0% ± 1.2% and 5.9% ± 0.8%. Five‐year EFS and CIR were 86.8% ± 1.6% and 8.7% ± 1.3% in non‐HR patients ( n = 470); 71.9% ± 2.3% and 18.0% ± 1.9% in HR patients ( n = 402). High PCR‐MRD levels at EOI and EOC were prognostic in all models, with EOC‐MRD ≥ 5 × 10 −3 related to a hazard ratio of 6.22 (P < 0.001). When a model considered factors identified at EOI only, central nervous system (CNS)3 (hazard ratio = 2.3, P < 0.001), PPR (hazard ratio = 1.74, P = 0.02), and high EOI‐MRD (hazard ratio 4.71 for ≥5 × 10 −2 vs. negative, P < 0.001) significantly impacted EFS. Results of T‐ALL patients in AIEOP‐BFM ALL 2009 were favorable. While EOC‐MRD remained the strongest prognostic predictor, PPR, CNS3 disease, and EOI‐MRD showed relevant prognostic value, with CNS3 and EOI‐MRD ≥ 5 × 10 −2 being candidate criteria for early stratification and intervention modifications.
Year:
2025
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.
Year:
2024
PURPOSE This study aimed to describe and assess the regional experience of a pediatric hematology/oncology fellowship program based in Guatemala. METHODS The Unidad Nacional de Oncología Pediátrica (UNOP) in Guatemala City, Guatemala, is the only hospital in Central America dedicated exclusively to childhood and adolescent cancer. To address the regional need for specialists, a fellowship program in pediatric hematology/oncology was launched in 2003. The UNOP fellowship program comprises 3 years of training. Although the program is based at UNOP, it also includes rotations locally and internationally to enhance clinical exposure. The curriculum is based on international standards to cover clinical expertise, research, professionalism, communication, and health advocacy. Trainees are selected according to country or facility-level need for pediatric hematologists/oncologists, with a plan for them to be hired immediately after completing their training. RESULTS Forty physicians from 10 countries in Latin America have completed training. In addition, there are currently 13 fellows from five countries in training. Of the graduates, 39 (98%) are now practicing in pediatric hematology/oncology in Latin America. Moreover, many of them have leadership positions within their institutions and participate in research, advocacy, and policy making. Graduates from the UNOP program contribute to institutions by providing care for an increasing number of patients with pediatric cancer. The UNOP program is the first pediatric hematology/oncology fellowship program in the world to be accredited by Accreditation Council for Graduate Medical Education-International, an international body accrediting clinical training programs. CONCLUSION The UNOP program has trained specialists to increase the available care for children with cancer in Latin America. This regional approach to specialist training can maximize resources and serve as a model for other programs and regions.
Year:
2024
Year:
2023
Collaborators (36)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Mariko Eguchi
Profesor
Ehime University Graduate School of Medicine
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
Martin Schrappe
-
riccardo masetti
Assistant Professor
University of Bologna
Kjeld Schmiegelow
-
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Filippo Spreafico
Istituto Giannina Gaslini
Atsushi Manabe
Professor
Hokkaido University
Gabriele Escherich
-
Maura Massimino
Direttore S.C
Fondazione IRCCS Istituto Nazionale dei Tumori
John Choi
The University of Alabama
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Daniel Ebrahimi‐Fakhari
University Hospital Münster
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Kathryn Roberts
St. Jude Children's Research Hospital
David Teachey
Professor
Children's Hospital of Philadelphia
Daisuke Tomizawa
Head
National Center For Child Health and Development
Carlos Rodriguez-Galindo
EVP/Chair
St. Jude Children's Research Hospital
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Sandra Luna-Fineman
Professor
University of Denver
Motohiro Kato
-
Takao Deguchi
Head of Division
National Center For Child Health and Development
Daniel DeAngelo
Chief of the Division of Leukemia
Dana-Farber Cancer Institute
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Masatoshi Takagi
Tokyo Medical and Dental University
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Make your next move.
Prepare your application
Review drafts before you send them.